Evidence map›Paper›PMID 39775131›Full record

ArticleScientific reports2025

Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression.

Steffen Markus Heckl, Carolin Schneider, Lukas Kercher, Hans-Michael Behrens, Jan-Paul Gundlach, Alexander Bernsmeier, Stephan Schmidt, Sandra Krüger, Felix Braun, Rainer Günther and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Steffen Markus Heckl *Department of Pathology, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany. steffen.heckl@uksh.de.
Carolin Schneider *Department of Pathology, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Lukas KercherDepartment of Pathology, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Hans-Michael BehrensDepartment of Pathology, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Jan-Paul GundlachDepartment of General, Visceral, Thoracic, Transplant and Pediatric Surgery, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Alexander BernsmeierDepartment of General, Visceral, Thoracic, Transplant and Pediatric Surgery, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Stephan SchmidtDepartment of General, Visceral, Thoracic, Transplant and Pediatric Surgery, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Sandra KrügerDepartment of Pathology, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Felix BraunDepartment of General, Visceral, Thoracic, Transplant and Pediatric Surgery, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Rainer GüntherDepartment of Internal Medicine I, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Thomas BeckerDepartment of General, Visceral, Thoracic, Transplant and Pediatric Surgery, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Stefan SchreiberDepartment of Internal Medicine I, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Christoph RöckenDepartment of Pathology, Christian-Albrechts-University, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular cancer (HCC) therapy is in need for an ideal companion diagnostic. Preclinical experimental studies have identified the insulin receptor (IR) and its synergistic counterpart, the IGF1 receptor (IGF1R), as relevant in HCC development, and the ligands IGF1 and IGF2 have been found to be elevated in HCC. This study aimed to bridge the gap to the clinical setting and explore whether the IR or the IGF1R would be of prognostic significance and would be associated with clinicopathologic parameters in HCC patients. In our retrospective cohort study located at the University Hospital Schleswig-Holstein, Campus Kiel, Germany, HCC samples of 139 patients were examined for IR and IGF1R expression by immunohistochemistry. A HistoScore was correlated with clinicopathological characteristics and survival. IR overexpression was frequently observed and was associated with clinicopathological parameters and survival. Membranous IR expression was associated with worse tumor specific survival (p = 0.043). Intriguingly, membranous IR expression was associated with worse tumor specific survival (p = 0.017) in the subgroup of patients undergoing sorafenib therapy. IGF1R expression was not associated with survival. In conclusion, our results suggest that membranous IR expression plays a role in HCC prognosis and treatment resistance, inspiring future validation as a potential companion diagnostic in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsReceptor, IGF Type 1Receptor, InsulinAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSorafenibBiomarkers, TumorIGF1R protein, humanReceptor, IGF Type 1Receptor, InsulinSorafenibHepatocellular cancerIGF1 receptorInsulin receptorPrognosisSorafenib

Identifiers

PMID39775131
PMCPMC11707270

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.